
Roche

A sustainable business model based on innovation and productivity gains

Karl Mahler, Head of Investor Relations





This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as “believes”, “expects”, “anticipates”, “projects”, “intends”, “should”, “seeks”, “estimates”, “future” or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, including among others:

- (1) pricing and product initiatives of competitors;
- (2) legislative and regulatory developments and economic conditions;
- (3) delay or inability in obtaining regulatory approvals or bringing products to market;
- (4) developments in financial market conditions, including the market for acquisition financing and other capital markets and fluctuations in currency exchange rates;
- (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects and unexpected side-effects of pipeline or marketed products;
- (6) increased government pricing pressures or changes in third party reimbursement rates;
- (7) interruptions in production;
- (8) loss of or inability to obtain adequate protection for intellectual property rights;
- (9) Litigation;
- (10) the inherent uncertainties involved in negotiations with the special committee of Genentech and that there can be no assurances that a negotiated transaction will ultimately be agreed to or consummated;
- (11) potential difficulties in integrating the businesses of Genentech and Roche, and that some or all of the anticipated benefits of the proposed transaction may not be realized on the schedule contemplated or at all;
- (12) that future dividends are subject to the discretion of the board of directors of Roche and a number of other factors, some of which are beyond the control of Roche;
- (13) the ability of Roche to generate cash flow to, among other things, repay acquisition-related debt as currently contemplated;
- (14) loss of key executives or other employees; and
- (15) adverse publicity and news coverage.

The directors of Genentech who are also employees of Roche will not take part in the consideration of the proposed transaction by the Genentech board and accordingly are not permitted to comment or respond to questions regarding the transaction as representatives of Genentech.

For marketed products discussed in this presentation, please see full prescribing information on our website – www.roche.com

All mentioned trademarks are legally protected.

Performance up-date

Strategy

Main trends influencing long term value propositions

Summary

Q1 2009: High single-digit growth for both divisions

Well above world market

| CHF bn | Q1'08 | Q1'09 | % change in | |
|------------------------|-------------|-------------|-------------|----------|
| | | | CHF | local |
| Pharmaceuticals | 8.6 | 9.2 | 8 | 8 |
| Diagnostics | 2.3 | 2.4 | 3 | 8 |
| Roche Group | 10.9 | 11.6 | 7 | 8 |


Performance up-date

Our Strategy and the changing environment

Main trends influencing long term value propositions

Summary

Roche's unique window of opportunity



The industry

Low replacement power of current earnings levels

Poor pipelines

Cost cutting


Roche

Extended stability

Low generic exposure


Investment into the future

Focus on our core businesses






Roche's strategy focuses along either dimension



Not to invest in the future means being out of business in ten years




*Source: www.fda.gov/fdac/graphics/newdrugspecial/drugchart.pdf


A well risk balanced approach to investment

Most projects in late stage de-risked

% of Pharma Development spend



Proof of Concept




* Formal decision to move into phase III pending




Responsible management of R&D spend

Higher attrition in early stage - higher success in late stage

Preclinical, Phase I and II



Phase III and Registration



Source: R&D General Metrics Study, KMR GROUP, INC

Performance up-date


Strategy

Main trends influencing long term value propositions

Personalized Healthcare- Roche best positioned

Summary

Main trends influencing the long-term value propositions




Personalised Healthcare


Maximizing assets on hand

Personalised Healthcare


Increasing demand by stakeholders




Best treatment



Better efficacy & safety profile




Better cost / benefit




More competitive

Scenarios for PHC Added Value Distribution

Value captured by different stakeholders depending on IP and timing of diagnostic




Main trends influencing the long-term value propositions



Key drivers for long term development in place




Develop the short term drivers while not neglecting the long term opportunities



Oncology franchise approaches CHF 20 billion in sales



Oncology sales (CHF billion)



Double-digit growth continues

Europe/RoW


- Continued strong increase in Avastin sales, driven by strong uptake in mCRC and mBC
- Emerging markets contributing to continued growth of MabThera, Herceptin and Tarceva

Japan

- Strong launches of Avastin, Tarceva, and adjuvant Herceptin

Major growth opportunities outside the US for key products

% of sales




■ EU / ROW (incl. Japan)
 ■ Nth America

Each cancer type is different

And needs a specific treatment approach

Incidence



Survival

| | | | |
|--------------------------|-----------|-----------|-----------|
| Adjuvant DFS at 3 years* | 72 % | 81 % | 50 % |
| Metastatic median OS * | 25 months | 36 months | 11 months |

* Assuming best current care, Incidence: GLOBOCAN 2002 and Roche market research


First in class mechanisms establishing new standards of care

| Rank | Drug | Sales (\$m) MAT 3Q08 |
|------|------------------|----------------------|
| 1 | MabThera | 4,189 |
| 2 | Herceptin | 4,129 |
| 3 | Avastin | 4,052 |
| 4 | Glivec | 3,491 |
| 5 | Taxotere | 2745 |
| 6 | Eloxatine | 2,236 |
| 7 | Arimidex | 1,944 |
| 8 | Gemzar | 1,601 |
| 9 | Erbitux | 1,412 |
| 10 | Casodex | 1,343 |

First in class

Successful products need to be first class entrants – the race begins early in R&D

Paradigm change: Development of all main cancer types in parallel



Avastin: significant potential for additional indications in the metastatic setting

Important Phase III newsflow over next 2 years

| Indication | Study name | Start | Status* | Filing* |
|---|----------------------------------|----------------|---|-----------|
| Previously-treated glioblastoma | BRAIN | 2007 | May 5, 2009 US FDA granted accelerated approval | 2008 |
| 1st line metastatic ovarian cancer | GOG-0218 ICON-7 | Q3'05 Q4'06 | Interim analysis H2'09 Expect data 2010 | 2010 |
| Relapsed Platinum sensitive ovarian cancer | OCEANS GOG-0213 | Q2'07 Q4'07 | Expect data 2010 Expect data 2013 | 2010-2013 |
| 1st line hormone-refractory prostate cancer | CALGB 90401 | Q4'07 | Interim analyses Q2'09 and Q4'09 | 2011 |
| 1st line advanced gastric cancer | AVAGAST | Q3'07 | Interim analysis H2'09 | 2010 |

*Projected timelines for positive results

Exciting mid / early-stage opportunities in oncology

3rd generation anti-CD20- potential for improvement over MabThera based on Glycart technology

Improved product features

Increased direct cell death

Increased ADCC

Lower CDC

Phase I in NHL

Extended patent life for many other monoclonal antibodies?

MabThera

Herceptin

Pertuzumab.

**GA101: Phase II ongoing
Phase I data presented at ASH 2009**

ASCO 2009 Highlights

Avastin

NSABP C-08: Adjuvant colon cancer efficacy results – late-breaker abstract

RIBBON-1: 1st line HER2-negative metastatic breast cancer – oral presentation

Tarceva

ATLAS: 1st line maintenance therapy for advanced non-small cell lung cancer – late-breaker oral presentation

SATURN: 1st line maintenance therapy for advanced non-small cell lung cancer – oral presentation

SATURN: 1st line maintenance therapy for advanced non-small cell lung cancer biomarker data

Herceptin

ToGA: 1st line HER2-positive advanced gastric cancer – oral presentation

T-DM1

Phase II second-line+ HER2-positive mBC final results

**Joint Roche-Genentech
Investor Science Events**


Sunday May 31st

Monday June 1st


Key drivers for long term development in place



Develop the short term drivers while not neglecting the long term opportunities




Rheumatoid Arthritis: Not all patients respond to current therapy



Comprehensive development program in RA

Covers all treatment stages

MabThera



* Indication not yet approved, awaiting regulatory approval

** Phase III trial in progress

Performance up-date


Strategy

Main trends influencing long term value propositions

Summary

Roche Pharma pipeline overview

Focused on five Disease Biology Areas



On Hand


Promising Late Stage

Emerging Mid-Term

Early Stage

Profitability measures


Operating cash flow per employee





Roche: M&D and G&A % to sales


Freeing up resources for innovation



Patent expiry 2008-2012

Roche short-/medium-term has the strongest patent protected portfolio... and highest share of biotech products

Top 10 Corporations Protected Sales Expiring to 2012 & Beyond (US\$ Const)



Source: IMS Health MIDAS Market Segmentation MAT June 2008, Ethical protected brand sales only.

Roche: A unique “investment case”

Clear and focused strategy

- Medically differentiated products
- Poised to become leader in Personalised Healthcare

Attractive risk profile

- Low generic risk; lowest among European large-cap players

Assets in place for sustained success

- World market leader in Oncology
- Emerging Rheumatology & Autoimmune, and Metabolic franchises

Industry-leading organic growth

Unique high-tech healthcare investment




We Innovate Healthcare

Avastin in mCRC: Strong uptake continues


First line

Patient share




Second line

Patient share



Top 10 Oncology Products

Sales and market shares in seven major markets in 2007



Roche/Genetech's MabThera, Herceptin and Avastin

dominate the current cancer brands market